Table 7. Overall Qualitative Summary.
Survival Relationship | Pathology Relationship | |||||
Pathway | Michigan | France | Japan | Michigan | France | Japan |
Cell Cycle (+) | X (poor) | X (poor) | CIS (−); Acinar (+); Pap (−); Solid (+) | CIS (−); Pap (−); Solid (+) | ||
ESC | ||||||
B-cell | X (good) | Acinar (−) | ||||
T-cell | ||||||
Antigen | X(good) | |||||
AKT/PI3K | X (poor) | X (poor) | Pap (−) | Acinar (+); Solid (−) | ||
IGF-1 | X (good) | Acinar (+); Pap (−) | Acinar (+); Pap (+) | |||
Chemokine | ||||||
NF-κB | ||||||
Notch | X (poor) | Pap (+); Solid (−) | Acinar (+) | |||
JAK/STAT | X (poor) | |||||
Complement | X (good) | Acinar (+); Solid (−) | Pap (+); Solid (−) | |||
mTOR | X (poor) | X (poor) | Acinar (−) | Solid (+) | ||
Cell Cycle (−) | X (good) | Acinar (−) | Acinar (+); Pap (−) | |||
Angiogenesis | X (poor) | Acinar (−); Pap (−); Solid (+) | CIS (+); Acinar (−) | CIS (−) | ||
IL-stimulatory | X (poor) | CIS (−) | CIS (−); Acinar (+); Pap (+); Solid (−) | Acinar (−) | ||
IL-suppressive | X (poor) | |||||
Interferon | X (good) | Pap (+) | ||||
EGFR | X (good) | Acinar (−); Pap (+) | Pap (+) | |||
PDGF | X (poor) | Acinar (+) | Acinar (+) | CIS (+); Pap (−); Solid (+) | ||
Hypoxia | X (poor) | Pap (+) | Acinar (+) | |||
PTEN | ||||||
Pro-apoptosis | X (good) | CIS (−) | ||||
Anti-apoptosis | Solid (+) | |||||
TGF-β | Pap (−); Solid (+) | |||||
Hedgehog | X (poor) | Pap (+); Solid (−) | ||||
Wnt | Solid (−) | Acinar (+); Solid (−) | Solid (−) |
An overall qualitative summary. Items in italics indicate validation in two or three of the three datasets. Abbreviations: poor, statistically poor survival; good, statistically good survival; CIS, carcinoma in situ; Pap, papillary; (+), statistically significant positive association between pathway and given subtype; (−), statistically significant negative association between pathway and given subtype.